Renesas Electronics Corporation (RNECY)
OTCMKTS · Delayed Price · Currency is USD
5.97
-0.09 (-1.49%)
Aug 1, 2025, 3:55 PM EDT
Inozyme Pharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Revenue | 1,272,193 | 1,348,479 | 1,469,415 | 1,500,853 | 993,908 | 715,673 | Upgrade |
Revenue Growth (YoY) | -12.38% | -8.23% | -2.10% | 51.01% | 38.88% | -0.36% | Upgrade |
Cost of Revenue | 563,987 | 596,083 | 634,787 | 641,222 | 449,564 | 379,684 | Upgrade |
Gross Profit | 708,206 | 752,396 | 834,628 | 859,631 | 544,344 | 335,989 | Upgrade |
Selling, General & Admin | 537,238 | 524,282 | 465,775 | 426,861 | 311,594 | 266,268 | Upgrade |
Other Operating Expenses | -6,937 | -13,931 | -2,450 | 6,045 | 3,058 | 589 | Upgrade |
Operating Expenses | 530,301 | 510,351 | 463,325 | 432,906 | 314,652 | 266,857 | Upgrade |
Operating Income | 177,905 | 242,045 | 371,303 | 426,725 | 229,692 | 69,132 | Upgrade |
Interest Expense | -241,572 | -10,918 | -6,339 | -6,867 | -9,946 | -7,541 | Upgrade |
Interest & Investment Income | 2,534 | 20,708 | 21,876 | 1,084 | 243 | - | Upgrade |
Earnings From Equity Investments | -510 | -272 | - | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 15,075 | 15,075 | 8,560 | -51,912 | -24,167 | 5,295 | Upgrade |
Other Non Operating Income (Expenses) | 1,468 | 1,468 | 1,002 | -3,913 | -768 | 582 | Upgrade |
EBT Excluding Unusual Items | -45,100 | 268,106 | 396,402 | 365,117 | 195,054 | 67,468 | Upgrade |
Merger & Restructuring Charges | -15,203 | -11,045 | -6,985 | -4,360 | -21,955 | -4,137 | Upgrade |
Gain (Loss) on Sale of Investments | 14,795 | 14,795 | 6,308 | - | 3,529 | 1,738 | Upgrade |
Gain (Loss) on Sale of Assets | -2,528 | - | - | 9,749 | 5,618 | 762 | Upgrade |
Asset Writedown | -16,992 | -7,894 | -5,940 | -7,719 | -135 | -2,070 | Upgrade |
Legal Settlements | -5,826 | - | - | -14 | -4,737 | -633 | Upgrade |
Other Unusual Items | -1,322 | -716 | 1,723 | -1,941 | -35,116 | -300 | Upgrade |
Pretax Income | -71,440 | 263,833 | 422,173 | 362,299 | 142,718 | 65,216 | Upgrade |
Income Tax Expense | 24,202 | 44,411 | 84,862 | 105,512 | 23,031 | 19,490 | Upgrade |
Earnings From Continuing Operations | -95,642 | 219,422 | 337,311 | 256,787 | 119,687 | 45,726 | Upgrade |
Minority Interest in Earnings | -203 | -338 | -225 | -155 | -151 | -100 | Upgrade |
Net Income | -95,845 | 219,084 | 337,086 | 256,632 | 119,536 | 45,626 | Upgrade |
Net Income to Common | -95,845 | 219,084 | 337,086 | 256,632 | 119,536 | 45,626 | Upgrade |
Net Income Growth | - | -35.01% | 31.35% | 114.69% | 161.99% | - | Upgrade |
Shares Outstanding (Basic) | 1,797 | 1,788 | 1,776 | 1,864 | 1,846 | 1,719 | Upgrade |
Shares Outstanding (Diluted) | 1,797 | 1,813 | 1,812 | 1,903 | 1,887 | 1,757 | Upgrade |
Shares Change (YoY) | -0.62% | 0.07% | -4.81% | 0.86% | 7.40% | 3.71% | Upgrade |
EPS (Basic) | -53.34 | 122.51 | 189.77 | 137.67 | 64.77 | 26.54 | Upgrade |
EPS (Diluted) | -53.34 | 120.85 | 186.07 | 134.85 | 63.35 | 25.97 | Upgrade |
EPS Growth | - | -35.05% | 37.98% | 112.86% | 143.94% | - | Upgrade |
Free Cash Flow | 227,834 | 210,595 | 408,404 | 413,190 | 270,446 | 201,628 | Upgrade |
Free Cash Flow Per Share | 126.79 | 116.17 | 225.44 | 217.11 | 143.32 | 114.75 | Upgrade |
Dividend Per Share | 28.000 | 28.000 | 28.000 | - | - | - | Upgrade |
Gross Margin | 55.67% | 55.80% | 56.80% | 57.28% | 54.77% | 46.95% | Upgrade |
Operating Margin | 13.98% | 17.95% | 25.27% | 28.43% | 23.11% | 9.66% | Upgrade |
Profit Margin | -7.53% | 16.25% | 22.94% | 17.10% | 12.03% | 6.38% | Upgrade |
Free Cash Flow Margin | 17.91% | 15.62% | 27.79% | 27.53% | 27.21% | 28.17% | Upgrade |
EBITDA | 276,028 | 340,957 | 459,956 | 516,817 | 307,175 | 150,829 | Upgrade |
EBITDA Margin | 21.70% | 25.29% | 31.30% | 34.44% | 30.91% | 21.07% | Upgrade |
D&A For EBITDA | 98,123 | 98,912 | 88,653 | 90,092 | 77,483 | 81,697 | Upgrade |
EBIT | 177,905 | 242,045 | 371,303 | 426,725 | 229,692 | 69,132 | Upgrade |
EBIT Margin | 13.98% | 17.95% | 25.27% | 28.43% | 23.11% | 9.66% | Upgrade |
Effective Tax Rate | - | 16.83% | 20.10% | 29.12% | 16.14% | 29.89% | Upgrade |
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.